What is the Bajaj Healthcare PE ratio today?
Bajaj Healthcare's PE ratio is 51.1 at the 29 October 2026 close (₹312.85 a share): a market capitalisation of ₹1,053 crore divided by consolidated net profit of ₹20.6 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit (₹15.8 crore) it is 66.8. These four quarters include net exceptional items of −₹33.2 crore (one-off charges reported separately), so the ratio on recurring profit would differ.
What is the Bajaj Healthcare PB ratio (price to book value)?
Bajaj Healthcare's price-to-book (PB) ratio is 1.89 at the 29 October 2026 close: a market capitalisation of ₹1,053 crore divided by shareholders' equity (book value) of ₹557 crore on 30 September 2026. That is a book value of ₹165.50 per share against a share price of ₹312.85.
What is the Bajaj Healthcare ROE and ROCE?
In FY26, Bajaj Healthcare's return on equity (ROE) was 3.2% and its return on capital employed (ROCE) was 13.3%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 10.6% and ROCE 11.5%.
What is the Bajaj Healthcare market cap?
Bajaj Healthcare's market capitalisation was ₹1,053 crore at the 29 October 2026 close: 3.37 crore shares at ₹312.85 each.
Is Bajaj Healthcare debt free?
No. Bajaj Healthcare had borrowings of ₹268 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.48. Its cash and current investments were ₹14.2 crore, so its net debt was ₹253 crore.
What is the Bajaj Healthcare EPS?
Bajaj Healthcare's basic earnings per share (EPS) were ₹4.98 in FY26, against ₹13.29 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹6.06.
What is the Bajaj Healthcare debt to equity ratio?
Bajaj Healthcare's debt-to-equity ratio was 0.48 on 30 September 2026: borrowings of ₹268 crore against total equity of ₹557 crore. A year earlier, on 30 September 2025, it was 0.45.
What is the Bajaj Healthcare net worth?
Bajaj Healthcare's net worth — shareholders' equity in its consolidated balance sheet — was ₹557 crore on 30 September 2026, up 14.5% from ₹486 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹1,053 crore at the 29 October 2026 close.
What is the Bajaj Healthcare dividend yield?
Bajaj Healthcare's dividend yield is 0.48% at the 29 October 2026 close: dividends of ₹1.50 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹312.85. They were ₹1.50 on 11 September 2026.
What is the Bajaj Healthcare book value per share?
Bajaj Healthcare's book value per share was ₹165.50 on 30 September 2026: shareholders' equity of ₹557 crore divided by the 3.37 crore shares in issue, up 7.5% from ₹154.00 a year earlier. The share price at the 29 October 2026 close was ₹312.85.
What are the Bajaj Healthcare latest quarterly results?
Bajaj Healthcare's latest results are for Q2 FY27 (July–September 2026), filed on 17 October 2026: consolidated net profit ₹14.1 crore, up 26.9% from ₹11.1 crore in Q2 FY26; revenue from operations ₹176 crore, up 18.9% year on year.
What is the Bajaj Healthcare revenue and profit in FY26?
In FY26 (April 2025–March 2026), Bajaj Healthcare's consolidated net profit was ₹15.8 crore, down 60.1% from ₹39.5 crore in FY25, on revenue from operations of ₹611 crore (up 12.6%). Over three years, from FY23, net profit was down 63.4%.
What is the Bajaj Healthcare dividend in 2026 and its record date?
In 2026, Bajaj Healthcare has declared one dividend: ₹1.50 with record date 14 September 2026 and ex-date 11 September 2026.
What is the Bajaj Healthcare promoter holding?
Promoters held 58.59% of Bajaj Healthcare on 30 September 2026, unchanged from the previous quarter and down 0.60 percentage points from 59.19% a year earlier, according to the shareholding pattern filed with NSE.
What is the Bajaj Healthcare free cash flow?
In FY26, Bajaj Healthcare generated ₹58.1 crore of cash from operations and spent ₹43.3 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹14.7 crore. In FY25 it was ₹10.1 crore.
What is the Bajaj Healthcare shareholding pattern?
On 30 September 2026, Bajaj Healthcare's shares were held by promoters 58.59%, foreign portfolio investors (FII/FPI) 2.09%, domestic institutions (DII) 1.96% (including mutual funds at 1.69%) and retail and other non-institutional investors 37.36%. Over the year, FII holding was up 0.97 percentage points from 1.12% and DII holding was down 1.04 percentage points from 3.00%.
How does the Bajaj Healthcare PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit, Bajaj Healthcare's PE ratio is 66.8, the second highest of the three: Themis Medicare 785.2 and Lincoln Pharmaceuticals 11.6, a peer average of 398.4. Each is the company's market capitalisation at that price divided by its FY26 net profit.
Bajaj Healthcare vs Themis Medicare: how do they compare?
In FY26, Bajaj Healthcare earned net profit of ₹15.8 crore on revenue of ₹611 crore, against ₹1.1 crore on ₹342 crore for Themis Medicare. Bajaj Healthcare's operating margin was 12.7% (Themis Medicare −2.9%) and its return on equity 3.2% (Themis Medicare 0.3%). At the 29 October 2026 close, Bajaj Healthcare's market capitalisation was ₹1,053 crore against ₹898 crore for Themis Medicare, and its PE ratio on FY26 profit 66.8 against 785.2.
When are the Bajaj Healthcare next results?
Bajaj Healthcare has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
How does Bajaj Healthcare compare with its peers?
On FY26 consolidated figures, against Themis Medicare and Lincoln Pharmaceuticals: Bajaj Healthcare's operating margin of 12.7% is the highest of the three (Themis Medicare −2.9%, Lincoln Pharmaceuticals 12.4%; peer average 4.8%); its return on equity of 3.2% is the second highest of the three (Themis Medicare 0.3%, Lincoln Pharmaceuticals 12.3%; peer average 6.3%); its revenue growth over three years of −3.2% a year is the lowest of the three (Themis Medicare −1.2% a year, Lincoln Pharmaceuticals 9.6% a year; peer average 4.2% a year).
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
